The Center for Medicare and Medicaid Services' final national coverage determination for amyloid-clearing monoclonal antibodies does not open the door further for Biogen, Inc.’s Aduhelm (aducanumab), but it will provide a boost for other Alzheimer's disease candidates.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?